IL240825B - Dihydropyridazine 3, 5-dione derivative - Google Patents

Dihydropyridazine 3, 5-dione derivative

Info

Publication number
IL240825B
IL240825B IL240825A IL24082515A IL240825B IL 240825 B IL240825 B IL 240825B IL 240825 A IL240825 A IL 240825A IL 24082515 A IL24082515 A IL 24082515A IL 240825 B IL240825 B IL 240825B
Authority
IL
Israel
Prior art keywords
dihydropyridazine
dione derivative
dione
derivative
Prior art date
Application number
IL240825A
Other languages
English (en)
Hebrew (he)
Other versions
IL240825A0 (en
Inventor
Ohtake Yoshihito
Okamoto Naoki
Ono Yoshiyuki
Kashiwagi Hirotaka
Kimbara Atsushi
Harada Takeo
Tachibana Kazutaka
Tanaka Shota
Nomura Kenichi
Ide Mitsuaki
Mizuguchi Eisaku
Ichida Yasuhiro
Ohtomo Shuichi
Horiba Naoshi
Hori Nobuyuki
Murata Yoshihisa
Original Assignee
Chugai Pharmaceutical Co Ltd
Ohtake Yoshihito
Okamoto Naoki
Ono Yoshiyuki
Kashiwagi Hirotaka
Kimbara Atsushi
Harada Takeo
Tachibana Kazutaka
Tanaka Shota
Nomura Kenichi
Ide Mitsuaki
Mizuguchi Eisaku
Ichida Yasuhiro
Ohtomo Shuichi
Horiba Naoshi
Hori Nobuyuki
Murata Yoshihisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Ohtake Yoshihito, Okamoto Naoki, Ono Yoshiyuki, Kashiwagi Hirotaka, Kimbara Atsushi, Harada Takeo, Tachibana Kazutaka, Tanaka Shota, Nomura Kenichi, Ide Mitsuaki, Mizuguchi Eisaku, Ichida Yasuhiro, Ohtomo Shuichi, Horiba Naoshi, Hori Nobuyuki, Murata Yoshihisa filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL240825A0 publication Critical patent/IL240825A0/en
Publication of IL240825B publication Critical patent/IL240825B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
IL240825A 2013-03-13 2015-08-25 Dihydropyridazine 3, 5-dione derivative IL240825B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25
PCT/JP2014/056778 WO2014142273A1 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン-3,5-ジオン誘導体

Publications (2)

Publication Number Publication Date
IL240825A0 IL240825A0 (en) 2015-10-29
IL240825B true IL240825B (en) 2020-07-30

Family

ID=51536921

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240825A IL240825B (en) 2013-03-13 2015-08-25 Dihydropyridazine 3, 5-dione derivative

Country Status (29)

Country Link
EP (2) EP3757093A1 (enExample)
JP (2) JP5814488B2 (enExample)
KR (2) KR102072268B1 (enExample)
CN (1) CN105073715B (enExample)
AU (1) AU2014230552B2 (enExample)
BR (1) BR112015022092B1 (enExample)
CA (1) CA2901868C (enExample)
CL (1) CL2015002543A1 (enExample)
CR (1) CR20150505A (enExample)
DK (1) DK2975030T3 (enExample)
ES (1) ES2811126T3 (enExample)
HR (1) HRP20201211T1 (enExample)
HU (1) HUE050577T2 (enExample)
IL (1) IL240825B (enExample)
LT (1) LT2975030T (enExample)
MX (1) MX376532B (enExample)
MY (1) MY174269A (enExample)
NZ (1) NZ711182A (enExample)
PE (1) PE20151535A1 (enExample)
PH (1) PH12015501940A1 (enExample)
PL (1) PL2975030T3 (enExample)
PT (1) PT2975030T (enExample)
RS (1) RS60911B1 (enExample)
RU (1) RU2662832C2 (enExample)
SG (1) SG11201507345RA (enExample)
SI (1) SI2975030T1 (enExample)
TW (2) TWI683811B (enExample)
UA (1) UA118755C2 (enExample)
WO (1) WO2014142273A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
EP4374877A3 (en) * 2014-09-12 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料(常州)有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
CN115734965B (zh) 2020-06-26 2025-05-02 日本农药株式会社 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
WO2022260064A1 (ja) 2021-06-08 2022-12-15 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤
AR126060A1 (es) * 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
CA3244263A1 (en) 2021-12-28 2025-06-13 Nihon Nohyaku Co., Ltd. ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND AND ASSOCIATED METHOD OF USE
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
TWI441637B (zh) * 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UA97498C2 (ru) * 2006-11-03 2012-02-27 Басф Се Способ получения дифторметилпиразолилкарбоксилатов
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN102264740B (zh) * 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
MX2012012421A (es) * 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2590965B1 (en) * 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative

Also Published As

Publication number Publication date
SI2975030T1 (sl) 2020-10-30
HUE050577T2 (hu) 2020-12-28
LT2975030T (lt) 2020-09-25
MY174269A (en) 2020-04-01
TW201446756A (zh) 2014-12-16
BR112015022092A8 (pt) 2018-01-23
HK1212700A1 (zh) 2016-06-17
CA2901868C (en) 2022-05-03
PE20151535A1 (es) 2015-10-28
JP6420738B2 (ja) 2018-11-07
JP2016040262A (ja) 2016-03-24
TW201741304A (zh) 2017-12-01
KR20160119282A (ko) 2016-10-12
BR112015022092B1 (pt) 2023-04-11
CR20150505A (es) 2015-10-26
EP2975030B1 (en) 2020-07-15
NZ711182A (en) 2020-05-29
DK2975030T3 (da) 2020-08-31
MX2015012537A (es) 2016-02-10
CN105073715B (zh) 2017-12-01
PH12015501940B1 (en) 2016-01-11
KR101664460B1 (ko) 2016-10-10
AU2014230552B2 (en) 2017-11-16
RS60911B1 (sr) 2020-11-30
MX376532B (es) 2025-03-07
PL2975030T3 (pl) 2021-01-11
EP2975030A4 (en) 2016-08-03
PT2975030T (pt) 2020-09-28
EP3757093A1 (en) 2020-12-30
KR20150127721A (ko) 2015-11-17
JPWO2014142273A1 (ja) 2017-02-16
ES2811126T3 (es) 2021-03-10
RU2662832C2 (ru) 2018-07-31
SG11201507345RA (en) 2015-10-29
TWI596095B (zh) 2017-08-21
AU2014230552A1 (en) 2015-08-13
WO2014142273A1 (ja) 2014-09-18
IL240825A0 (en) 2015-10-29
EP2975030A1 (en) 2016-01-20
CA2901868A1 (en) 2014-09-18
BR112015022092A2 (pt) 2017-07-18
PH12015501940A1 (en) 2016-01-11
CN105073715A (zh) 2015-11-18
JP5814488B2 (ja) 2015-11-17
CL2015002543A1 (es) 2016-02-26
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
HRP20201211T1 (hr) 2020-11-13
RU2015143507A (ru) 2017-04-19
KR102072268B1 (ko) 2020-01-31

Similar Documents

Publication Publication Date Title
IL240863B (en) Amatoxin derivatives
SG11201506100XA (en) Pyridazinone-amides derivatives
IL240825A0 (en) Dihydropyridazine 3, 5-dione derivative
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
IL240348A0 (en) Transmuted imidazopyridines
IL243273A0 (en) Converted pyrazolo-pyridineamines
IL246271A0 (en) Converted piperidinyl-tetrahydroquinolines
GB201411896D0 (en) .
IL241293A0 (en) triazole derivatives
SG11201605189YA (en) Imidazopyrazinone derivatives
IL241859B (en) Novel triazole derivatives
GB201417087D0 (en) No detials
SG11201505559PA (en) Router
GB201409791D0 (en) .
GB201322661D0 (en) .
GB201312935D0 (en) T,b,s
GB201308346D0 (en) Double ended match
GB201300322D0 (en) Beataboutmusic.com
GB201301396D0 (en) Ar
GB201300649D0 (en) Cyclization
AU352391S (en) Step
GB201305138D0 (en) Thresher
GB201313996D0 (en) Tradepad

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed